Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_assertion type Assertion NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_head.
- NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_assertion description "[The discovery of JAK2 and MPL mutations in patients with myeloproliferative neoplasms (MPNs) provided important insight into the genetic basis of these disorders and led to the development of JAK2 kinase inhibitors for MPN therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_provenance.
- NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_assertion evidence source_evidence_literature NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_provenance.
- NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_assertion SIO_000772 20154217 NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_provenance.
- NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_assertion wasDerivedFrom befree-20140225 NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_provenance.
- NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_assertion wasGeneratedBy ECO_0000203 NP501378.RAO-f6KIokurzQ4FRl59lWc4x5nk_gV4r2sSDNLXT83bk130_provenance.